GDTC חוב כולל להון CytoMed Therapeutics

CytoMed Therapeutics (GDTC) relies on a strong talent pool of immunologists and clinical research experts in Southeast Asia. This business is resilient to market downturns, as oncology remains a top priority. The historical debt-to-equity ratio stands at 0.09, linking the financial profile to the development of off-the-shelf NK-cell therapies that mitigate risks through mass application.

Analyzing the debt-to-equity ratio of CytoMed Therapeutics (GDTC) allows for an assessment of the biotech startup's financial stability during the development stage of gamma-delta T-cell therapies. This metric compares total liabilities to equity, where a market revaluation of assets following successful clinical trials reduces credit risk, confirming the company's ability to fund innovation without excessive debt leverage.